Minerva Neurosciences, Inc. Operating Lease, Right-of-Use Asset, Amortization Expense
Minerva Neurosciences, Inc. (NERV) reported Operating Lease, Right-of-Use Asset, Amortization Expense of $101.79 thousand for the 12-month period ending 2021-12-31, per its 10-K filed 2023-03-08.
Discontinued › Cash Flow › Operating Activities
us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense · last filed 2023-03-08
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-12-31 was $0.00.
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-09-30 was $14.94K.
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-06-30 was $44.01K.
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for the quarter ending 2021-03-31 was $42.83K.
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2021 was $101.79K, a 36.45% decline from fiscal 2020.
- Minerva Neurosciences, Inc. operating lease, right-of-use asset, amortization expense for fiscal 2020 was $160.17K.
| Period end | Operating Lease, Right-of-Use Asset, Amortization Expense 3 month | Operating Lease, Right-of-Use Asset, Amortization Expense 6 month | Operating Lease, Right-of-Use Asset, Amortization Expense 9 month | Operating Lease, Right-of-Use Asset, Amortization Expense 12 month |
|---|---|---|---|---|
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-08 | $14.94K derived: sum of 2 quarters · filed 2023-03-08 | $58.95K derived: sum of 3 quarters · filed 2023-03-08 | $101.79K 10-K · filed 2023-03-08 |
| 2021-09-30 | $14.94K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $58.95K derived: sum of 2 quarters · filed 2022-11-09 | $101.79K 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $44.01K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $86.85K 10-Q · filed 2022-08-09 | ||
| 2021-03-31 | $42.83K 10-Q · filed 2022-05-04 | |||
| 2020-12-31 | $160.17K 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |